CC BY-NC-ND 4.0 · Indian Journal of Cardiovascular Disease in Women WINCARS 2020; 5(03): 216-222
DOI: 10.1055/s-0040-1716786
Review Article

Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)

M. Jyotsna
1  Department of Cardiology, Nizams Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Y. Hemalatha
1  Department of Cardiology, Nizams Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
› Author Affiliations
  

Abstract

Coronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in India. The FDA for the prevention or treatment of COVID-19 has approved no drugs or biologics. Numerous other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as potential therapies. Searching for effective therapies for COVID-19 infection is a complex process. The cardiovascular disease (CVD) drugs and the COVID-19 treating drugs show potent drug–drug interactions (DDI), disease–drug interactions, and disease–disease interactions.



Publication History

Publication Date:
14 September 2020 (online)

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India